Self-injectable treatment for myasthenia gravis, Zilbrysq, wins Korean approval

The Ministry of Food and Drug Safety (MFDS) said on Thursday it approved UCB Korea's myasthenia gravis treatment, Zilbrysq Prefilled Syringe Injection (zilucoplan sodium).

Generalized myasthenia gravis is an antibody-mediated autoimmune disease characterized by chronic systemic or localized muscle weakness caused by autoantibodies that disrupt the neuromuscular junction.

Zilbrysq inhibits complement-mediated neuromuscular junction damage caused by anti-acetylcholine receptor autoantibodies and is therapeutically effective.

It is approved for use as an adjunct to standard therapy for the treatment of anti-acetylcholine receptor antibody-positive systemic myasthenia gravis in adults.

“This approval will expand the treatment options for adult patients with myasthenia gravis,” the MFDS said. “Zilbrysq can be self-administered by subcutaneous injection, providing convenience for patients.”